[go: up one dir, main page]

PE20081547A1 - THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT - Google Patents

THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT

Info

Publication number
PE20081547A1
PE20081547A1 PE2008000015A PE2008000015A PE20081547A1 PE 20081547 A1 PE20081547 A1 PE 20081547A1 PE 2008000015 A PE2008000015 A PE 2008000015A PE 2008000015 A PE2008000015 A PE 2008000015A PE 20081547 A1 PE20081547 A1 PE 20081547A1
Authority
PE
Peru
Prior art keywords
interleukin
antagonist
active ingredient
therapeutic agents
agents containing
Prior art date
Application number
PE2008000015A
Other languages
Spanish (es)
Inventor
Hitoshi Kohsaka
Nobuyuki Miyasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Nat Univ Corp Tokyo Med & Dent
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39562504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Nat Univ Corp Tokyo Med & Dent, Riken filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20081547A1 publication Critical patent/PE20081547A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN COMPUESTO ANTAGONISTA DE LA INTERLEUCINA 6 (IL-6) TAL COMO UN ANTICUERPO CONTRA EL RECEPTOR IL-6 O UN ANTICUERPO CONTRA IL-6, UN ANTICUERPO MONOCLONAL, UN ANTICUERPO RECOMBINANTE, UN ANTICUERPO QUIMERICO, HUMANIZADO O HUMANO. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE UNA MIOPATIA INFLAMATORIA TAL COMO MIOSITIS MULTIPLE O DERMATOMIOSITISREFERRED TO AN ANTAGONIST COMPOUND OF INTERLEUKIN 6 (IL-6) SUCH AS AN ANTIBODY AGAINST IL-6 RECEPTOR OR AN ANTIBODY AGAINST IL-6, A MONOCLONAL ANTIBODY, A RECOMBINANT ANTIBODY, A CHIMERIC OR HUMANIZED ANTIBODY. SAID COMPOUND IS USEFUL IN THE TREATMENT OF AN INFLAMMATORY MYOPATHY SUCH AS MULTIPLE MYOSITIS OR DERMATOMYOSITIS

PE2008000015A 2006-12-27 2008-01-02 THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT PE20081547A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006351695A JP2010095445A (en) 2006-12-27 2006-12-27 Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient

Publications (1)

Publication Number Publication Date
PE20081547A1 true PE20081547A1 (en) 2009-01-18

Family

ID=39562504

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000015A PE20081547A1 (en) 2006-12-27 2008-01-02 THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT

Country Status (5)

Country Link
JP (1) JP2010095445A (en)
AR (1) AR064538A1 (en)
CL (1) CL2007003817A1 (en)
PE (1) PE20081547A1 (en)
WO (1) WO2008078715A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
CN104998254A (en) 2010-11-08 2015-10-28 基因技术公司 Anti-IL-6 receptor antibody administered subcutaneously
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3630453B2 (en) * 1994-09-30 2005-03-16 中外製薬株式会社 A therapeutic agent for immature myeloma cells comprising an IL-6 receptor antibody as an active ingredient
CN101601861A (en) * 1994-10-07 2009-12-16 中外制药株式会社 Treatment of Chronic Rheumatoid Arthritis Using IL-6 Antagonist as Active Component
AU736282B2 (en) * 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
ES2299241T3 (en) * 1998-03-17 2008-05-16 Chugai Seiyaku Kabushiki Kaisha PREVENTIVES OR REMEDIES FOR INFLAMMATORY INTESTINAL DISEASES CONTAINING ANTAGONIST ANTIBODIES OF THE IL-6 RECEIVER.
AU757261B2 (en) * 1998-08-24 2003-02-13 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for pancreatitis containing IL-6 antagonists as the active ingredient
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PT1562968E (en) * 2001-11-14 2013-10-23 Janssen Biotech Inc Anti-il-6 antibodies, compositions, methods and uses
AR048210A1 (en) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.

Also Published As

Publication number Publication date
WO2008078715A1 (en) 2008-07-03
AR064538A1 (en) 2009-04-08
CL2007003817A1 (en) 2008-06-27
JP2010095445A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
PE20081547A1 (en) THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT
RU2010117171A (en) THERAPEUTIC AGENTS USED AGAINST REACTION TRANSPLANT AGAINST THE OWNER, CONTAINING AN INTERLEUKIN-6 RECEPTOR INHIBITOR AS AN ACTIVE INGREDIENT
EA201170676A1 (en) AGONISTS OF RECEPTOR MELANOCORTIN
CY1121402T1 (en) PERCENTIC COMPOSITIONS CONTAINING AN ACTIVE ISOXAZOLINE AGENTS, METHODS AND USES
RU2010127291A (en) THERAPEUTIC AGAINST ITCH
MY156702A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
UA108641C2 (en) PARASITICID COMPOSITION CONTAINING FOUR ACTIVE AGENTS AND METHOD OF APPLICATION
EA201492023A1 (en) REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION
UA110013C2 (en) APPLICATION OF THE COMPOSITION FOR THE TREATMENT OF BALL-MARI-HERE AND THE RELATED DISORDERS
EA200870292A1 (en) COMPOUNDS BASED ON IMIDAZOL, COMPOSITIONS CONTAINING THEM, AND METHODS OF THEIR APPLICATION
EA200970532A1 (en) FUMARATE SALT (ALPHA S, BETA R) -6-BRUM-ALPHA- [2- (DIMETHYLAMINO) ETHYL] -2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-HINOLINETHANOL
EA201001230A1 (en) PESTICIDAL MIXTURES
MX345032B (en) Selective ep4 receptor agonistic substance for treatment of cancer.
EA201400165A1 (en) PARTICLES BASED ON POLYACRYLATE THAT CONTAIN AN ACTIVE CONNECTION
CY1114163T1 (en) METHODS OF USE OF ANGIOPYCIN COMPETITORS WITH CARBON CYCLOTHERIC AGENTS TO REDUCE CARDIOTOXICITY AND / OR IMPROVEMENT
EA201001234A1 (en) PESTICIDAL MIXTURES
EA200602242A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS
ECSP066991A (en) 3- (4-HETEROARILCICLOHEXILAMINO) CYCLOPENTANOCARBOXAMIDS AS CHEMIOKIN RECEPTORS MODULATORS
EA201190163A1 (en) HUMANIZED ANTIBODY TO PcrV, possessing activity against PSEVDOMONAS
EA201391524A1 (en) GLYCOSIDE DERIVATIVES AND THEIR APPLICATION
ATE478856T1 (en) SPIROBENZODIOXOLS AND THEIR USE AS CB1 ANTAGONISTS
AR065597A1 (en) ESTER COMPOUND AND ITS USE
EA201301021A1 (en) APPLICATION OF A COMPOSITION CONTAINING AMBROADABLE CONTAINING AMBROXOL
GEP20125640B (en) Phenanthrenone compounds, compositions containing them and use thereof
HRP20090011T3 (en) 2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZDIAZEPIN-3-IL-PIPERIDINI KAO CGRP ANTAGONIST

Legal Events

Date Code Title Description
FA Abandonment or withdrawal